Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Centessa Pharmaceuticals (CNTA) Other financing activities (2022 - 2025)

Centessa Pharmaceuticals has reported Other financing activities over the past 2 years, most recently at -$5000.0 for Q4 2025.

Quarterly Other financing activities changed N/A to -$5000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$401000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$401000.0 for FY2025, N/A changed from the prior year.
Other financing activities was -$5000.0 for Q4 2025 at Centessa Pharmaceuticals, down from $4.4 million in the prior quarter.
Over five years, Other financing activities peaked at $4.4 million in Q2 2025 and troughed at -$4.8 million in Q1 2025.